Dan is the CEO of Vaneltix with a background as a pharmaceutical business development consultant with expertise in urology, immunology, CV, CNS and women's healthcare therapeutic areas, as well as expertise of special dosage forms and drug delivery. Dan is currently on the board of Vaneltix Pharmaceuticals and has held CEO, President, Chairman and managing consultants positions. He is an advisory board member of the Center for Molecular Medicine & Therapeutics and a past board member of the Interstial Cystitis Association, and he is a President's Circle member of the American Association for the Advancement of Science (AAAS). He has a Ph.D in Genetics and an MBA in General Management.